Abstract
The development of modern medicine experienced a major leap forward in the nineteenth century because of advances in science and, since then, the evolution of scientific knowledge has pushed forward the growth of the modern pharmaceutical industry (Gribbin and Hook, 2004). The progress in human understanding of bacteriology and related subjects had replaced traditional knowledge of epidemiology and chemistry (Wikipedia, 2007a, “History of medicine”). The hygiene theory advocated by Ignaz Semmelweis (1818–1865) in 1847 paved the way for the germ theory of disease. The germ theory was put into practice later when, in 1865, British surgeon Joseph Lister discovered the principles of antisepsis (ibid.). The discoveries made by Louis Pasteur that pinpointed microorganisms as a major cause of diseases gave birth to a major conceptual breakthrough in the making of therapeutics. Against this background, Pasteur’s invention of a vaccine against rabies in 1880 led to the success of other vaccine development (see Seppa, 18 and 25 December 1999). Pasteur’s experiments, which confirmed germ theory, had important implications for using scientific method in the making of medicine. This method was articulated in Pasteur’s book, An Introduction to the Study of Experimental Medicine in 1865. Pasteur and Robert Koch, who discovered tubercle bacillus in 1882, cholera bacillus in 1883, and Koch’s postulates, founded bacteriology (Wikipedia, 2007a).
Chapter PDF
References
AAAS (2008) “NIH wins $1 billion funding but veto looms.” Available at: http://www.aaas.org/spp/rd/nih08c.htm
American Medical Student Association (13 April, 2008) “Prescription drug importation: A short-term effort to reduce drug prices.” Available at: http://www.amsa.org/hp/reimportation.cfm
Angell, M. (2004) The Truth about the Drug Companies. New York: Random House.
Barry, P. (April 2003) “More Americans go North for drugs.” AARP Bulletin. Available at: http://www.aarp.org/bulletin/yourmoney/a2003-06-25-moreamericans.html
Bayer (2007) “Bayer: Science for a better life.” Available at: http://www.bayer.com/en/History.aspx
BBC (10 December 2003) “Aids activists say GlaxoSmithKline is to allow the manufacture of cheap generic drug versions in South Africa.” Available at: http://news.bbc.co.uk/2/hi/business/3306079.stm
Bekelman, J. E. et al. (22 January 2006) “Scope and impact of financial conflicts of interest in biomedical research.” Journal of the American Medical Association, p. 454.
Bioanalytical Systems Inc. (2007a) Bayer corporation. Available at: http://www.bioanalytical.com/info/calendar/99/01bayer.htm
Bioanalytical Systems Inc. (2007b) Eli Lily and Company. Available at: http://www.bioanalytical.com/info/calendar/99/04lilly.htm
Bioanalytical Systems Inc. (2007c) Hoechst Marion Roussel. Available at: http://www.bioanalytical.com/info/calendar/99/03hoech.htm
Bioanalytical Systems Inc. (2007d) Merck and Company Inc. Available at: http://www.bioanalytical.com/info/calendar/99/05merck.htm
Bioanalytical Systems Inc. (2007e) “The pharmaceutical industry: A history and calendar.” Available at: http://www.bioanalytical.com/info/calendar/99/07.html
Bioanalytical Systems Inc. (2007f) Pfizer. Available at: http://www.bioanalytical.com/info/calendar/99/07pfizer.htm
Bioanalytical Systems Inc. (2007g) SmithKline Beecham. Available at: http://www.bioanalytical.com/info/calendar/99/09smith.htm
Bioanalytical Systems Inc. (2007h) Wyeth Ayerst. Available at: http://www.bioanalytical.com/info/calendar/99/10wyeth.htm
Bristol-Myers Squibb (2006) “A Brief History of Bristol-Myers Squibb.” Available at: http://www.bms.com/aboutbms/content/data/ourhis.html
Cauchon, D. (25 September 2000) “FDA advisors tied to industry”. USA Today, 1A.
Center for Policy Alternatives (2000) “Playing fair: State action to lower prescription drug prices.” Available at: http://www.stateaction.org/issues/issue.cfm/issue/PrescriptionDrugPricing.xml
Centre of Public Integrity (7 July 2005) “Drug lobby second to none.” Available at: http://www.publicintegrity.org/rx/report.aspx?aid=723
Cptech (2001) “Pharmaceutical industry R&D costs: Key findings about the Public Citizen Report.” Available at: http://www.cptech.org/ip/health/econ/phrmaresponse.pdf
Darwin, C. (2003). The Origin of Species. New York: Signet Classics.
Denning, B. P. (2003) “The Maine Rx prescription drug plan and the ormant Commerce Clause Doctrine: The case of the missing link.” American Journal of Law and Medicine. Available at: http://papers.ssrn.com/sol3/papers.cfm?abstract_id=355303
Dictionary.com Unabridged, v 1.1 (2007) Random House.
Dobson, R. (28 April 2001) “Drug company lobbyist joins Oxfam’s cheap drugs campaign.” British Medical Journal, vol. 322, p. 1011.
Ebisch, R. (March 2005) “Prescription for change” Teradata Magazine on-line. Available at: http://www.teradata.com/t/page/131951/
Eli Lilly Company (2007) “History.” Available at: http://www.lilly.com/about/history.html.
European Commission (2007) “The 2007 EU industrial R&D investment scoreboard”. Available at: http://iri.jrc.ec.europa.eu/research/scoreboard_2007.htm
European Public Health Alliance, 2008, “UK parliamentarians put the pharma industry under the spotlight.” Available at: http://www.epha.org/a/1773
FDA Magazine (2006) “Wiley W. Harvey: Pioneer consumer activist.” Available at: http://www.fda.gov/fdac/features/2006/106_wiley.html
FDA (1997) “Food And Drug Administration and Modernization Act of 1997.” Available at: http://www.fda.gov/cder/guidance/105-115.htm
FDA (1983) “Orphan Drugs.” Available at: http://www.fda.gov/cder/handbook/orphan.htm
FierceBiotech (2007a) “The top 15 R&D Market.” Available at: http://www.fiercebiotech.com/special-reports/top-15-r-d-budgets
FierceBiotech (28 November 2007b) “Schering-Plough — Top 15 R&D Budgets.” Available at: http://www.fiercebiotech.com/special-reports/15-schering-plough-top-15r-d-budgets
FierceBiotech (28 November 2007c) “Amgen — Top 15 R&D.” Available at: http://www.fiercebiotech.com/special-reports/9-amgen-top-15-r-d-budgets
FierceBiotech (28 November 2007d) “Eli Lilly — Top 15 R&D.” Available at: http://www.fiercebiotech.com/special-reports/11-eli-lilly-top-15-r-d-budgets
FierceBiotech (28 November 2007e) “Merck — Top 15 R&Ds.” Available at: http://www.fiercebiotech.com/special-reports/7-merck-top-15-r-d-budgets
FierceBiotech (28 November 2007f). “Novartis — Top 15 R&D budget.” Available at: http://www.fiercebiotech.com/special-reports/6-novartis-top-15-r-d-budgets
FierceBiotech (28 February 2008a) “AstraZeneca may shake up R&D with spin-off.” Available at: http://www.fiercebioresearcher.com/story/astrazeneca-may-shake-up-rd-with-spin-off/2008-02-12
FierceBiotech (15 November 2008b) “Abbott — Top 15 R&D Budgets.” Available at: http://www.fiercebiotech.com/special-reports/14-abbott-top-15-r-d-budgets
FierceBiotech (28 November 2008c) “Bristol-Myers Squibb — Top 15 R&D Budgets.” Available at: http://www.fiercebiotech.com/special-reports/13-bristol-myers-squibb-top-15-r-d-budgets
Franklin Pierce Law Center (2008) “Overview of federal technology transfer.” Available at: http://www.fplc.edu/risk/vol5/spring/rudolph.htm
Fundinguniverse (2008) “Wyeth.” Available at: http://www.fundinguniverse.com/company-histories/Wyeth-Company-History.html
Gagnon, M.-A. and Lexchin. J. (3 January 2008) “The cost of pushing pills: A new estimate of pharmaceutical promotion expenditures in the United States.” PLOS Medicine Journal. Available at: http://medicine.plosjournals.org/perlserv/?request=get-document&doi=10.1371/journal.pmed.0050001&ct=1
Goozner, M. (2004) The $800 Million Pill: The Truth behind the Cost of New Drugs. Berkeley CA: University of California Press.
Gribbin, A. (18 June 2001) “House investigates panels involved with drug safety.” Washington Times.
Gribbin, J. and Hook A. (2004) The Scientists: A History of Science Told Through the Lives of Its Greatest Inventors. New York: Random House.
Griffiths, S. (March 2004) “Betting on biogenerics.” Nature Reviews Drug Discovery, vol. 3, pp. 197–8. Available at: http://www.nature.com/nrd/journal/v3/n3/full/nrd1333.html
GSK (2007) “Our company.” Available at: http://www.gsk.com/about/company.htm
GSK (2008) “Research and development.” Available at: http://www.gsk.com/research/about/index.html
Harris, G. (23 October, 2003) “Cheap drugs from Canada: Another political hot potato.” New York Times. Available at: http://biopsychiatry.com/pharmacy/canada.html
Hensley, S. and Martinez, B (15 July 2005) “To sell their drugs, companies increasingly rely on doctors.” Wall Street Journal, p. A1.
Herper, M. and Kang, P. (22 March 2006) “The world’s ten best-selling drugs.” Available at Forbes: http://www.forbes.com/home/sciencesandmedicine/2006/03/21/pfizer-merck-amgen-cx_mh_pk_0321topdrugs.html
Hoechst AG (2008) “Hoechst A.G.” Available at: http://www.fundinguniverse.com/company-histories/Hoechst-AG-Company-History.html IMS Reports (17 February 2004) “11.5 Percent Dollar Growth in ’03 U.S. Prescription Sales.” IMS Health. Available at: http://www.imshealth.com/ims/portal/front/article C/0,2777,6025_3665_44771558,00.html
IMS Reports (2007a) “IMS Health reports global pharmaceutical market grew 7.0 percent in 2006, to $643 Billion.” Available at: http://www.imshealth.com/ims/portal/front/articleC/0,2777,6025_3665_44771558,00.html
IMS Reports (8 March 2007b) “U.S. Prescription Sales Jump 8.3 Percent in 2006, to $274.9 Billion.” Available at: http://www.imshealth.com/ims/portal/front/articleC/0,2777,6025_3665_44771558,00.html
Ismail, M. A. (7 July, 2005) “Drug lobby second to none.” The Center for Public Integrity. Available at: http://www.publicintegrityorg/rx/report.aspx?aid=723
Johnson & Johnson (2007). “Innovations.” Available at: http://www.jnj.com/innovations/pharma_pipeline/index.htm
Kaufman, M. (6 May 2005) “Merck CEO Resigns as Drug Probe Continues.” A-1. Available at: http://www.washingtonpost.com/wp-dyn/content/article/2005/05/05/AR2005050501115_pf.html
Lamberti, M. J. (2001) An Industry in Evolution, 3rd edn. Boston, MA: CenterWatch, p. 22.
Larson, R. (2005) Bioinformatics and Drug Discovery. New York: Humana Press.
Le Monde (19 October 2007) “Pfizer et Novartis souffrent du succèss des mèdicaments gènètique.” Available at: http://www.lemonde.fr/web/article/0,1-0@2-3234,36-968860@51-968475,0.html
Lichtenberg, F. R. (11 July 2007) “Yes, new drugs save lives.” Washington Post, A15. Available at: http://www.washingtonpost.com/wp-dyn/content/article/2007/07/10/AR2007071001468.html.
Long, S. H. (Spring 1994) “Prescriptions drugs and the elderly: Issues and options.” Health Affairs, vol. ii, pp. 157–74.”
Mantone, J. (6 December 2007) “Big Pharma’s Bitter Pill.” Wall Street Journal. Available at: http://blogs.wsj.com/health/2007/12/06/big-pharmas-bitter-pill/?mod=WSJBlog
Martinez, B., and Goldstein, J. (6 December 2007) “Big Pharma Faces Grim Prognosis.” Wall Street Journal. Available at: http://online.wsj.com/article/SB119689933952615133.html?mod=WSJBlog
Martino, M. (2007) “Comments on top-15 R&D budget.” Available at: http://www.fiercebiotech.com/special-reports/top-15-r-d-budgets
McKinzie Productview (March 2007) “Global company sales summary.” Available at: http://www.p-d-r.com/ranking/2006_Company_Sales.pdf
Merck and Company (2002) “History of Merck.” Available at: http://www.msd.com.hk/about_us/e_history_of_merck.html
Moynihan, R. (31 May 2003a) “Drug company sponsorship of education could be replaced at a fraction of its cost.” British Medical Journal, vol. 326, no. 7400, p. 1163. Available at: http://www.bmj.com/cgi/content/full/326/7400/1163
Moynihan, R. (31 May 2003b) “Who pays for the pizza? Redefining the relationships between doctors and drug companies.” 2: “Disentanglement.” British Medical Journal, vol. 326, no. 7400, pp. 1193–6.
Moynihan, R. and Alan Cassels (2005) Selling Sickness: How Drug Companies are Turning Us All Into Patients. New York: Allen & Unwin.
Myers, Kelly D. (1 January 2007) Marketing to Professionals: Tomorrow’s Changes Today. Available at: PharmExec.com
National Cancer Institute (2007) “Menopausal hormone replacement therapy use and cancer: Questions and answers.” Available at: http://www.cancer.gov/cancertopics/factsheet/Risk/menopausal-hormones
Nature Reviews Drug Discovery (July 2006) “Editorial: Keeping sight of the goal.” Nature, vol. 5, p. 525. Available at: http://www.nature.com/nrd/journal/v5/n7/abs/nrd2102.html
Nelson, G. (1983) Pharmaceutical Companies Histories. Bethesda, MD: Woodbine House Publishing.
Newton, D. Thorpe, A. and Otter, C. (2004). Revise A2 Chemistry. New York: Heinemann Educational Publishing, p. 1.
No Free Lunch (2008) http://www.nofreelunch.org/
Osterloh, I. (June, 2007) “How I discovered viagra.” (An account by the executive director of discovery research at Pfizer Global Research & Development’s Sandwich Laboratories, England). Cosmos, issue 15. Available at: http://www.cosmosmagazine.com/node/1463
Oversteegen, L., Rovini, H., and Belsey M. J. (September 2007) “Respiratory drug market dynamics.” Nature Reviews Drug Discovery, vol. 6, pp. 695–6. Available at: http://www.nature.com/nrd/journal/v6/n9/full/nrd2401.html
Ozols, R. F. (1 January 2007) “Clinical cancer advances 2006: Major research advances in cancer treatment, prevention, and screening — A report from the American Society of Clinical Oncology.” Journal of Clinical Oncology, vol. 25, no. 1, pp. 146–62. Available at: http://www.cancer.org/docroot/NWS/content/NWS_1_1x_Targeted_Therapies_Vaccines_Among_Major_Cancer_Advances_in_2006.asp
Pagnamenta, R. (12 February 2008) “AstraZeneca may spin off drug research unit to venture capitalists.” Times on-line. Available at: http://business.timesonline.co.uk/tol/business/industry_sectors/health/article3352968.ece
Pear, R. (25 December 2002) “Law requiring lower drug prices is struck down.” Available at: http://query.nytimes.com/gst/fullpage.html?res=9E0CE7D9133CF936A15751C1A9649C8B63&sec=&spon=&pagewanted=all
Pfizer (2008a) “About Pfizer.” Available at: http://www.pfizer.com/about/history/2000_present.jsp
Pfizer Inc. (2008b) “Pfizer Inc and Hoechst Marion Roussel to co-develop and co-promote inhaled insulin.” Available at: http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/11-04-1998/0000793273&EDATE=
Pfizer (2008c) “Pfizer pipeline — new medicine in development.” Available at: http://www.pfizer.com/research/pipeline/pipeline.jsp
PLOS Medicine (2006) A Collection of Articles on Disease Mongering. Public Library of Science. Available at: http://collections.plos.org/plosmedicine/diseasemongering-2006.php
Prescription Access Litigation (2007) Available at: http://www.prescriptionaccess.org/
Privitera, M. D. (2003) “Phase IV trials: A wolf in sheep’s clothing?” The Annals of Pharmacotherapy, vol. 37, no. 5, pp. 741–3. Available at: http://www.thean-nals.com/cgi/content/full/37/5/741
Public Citizen Report (23 July 2001) “Rx R&D myths: The case against the drug industry’s R&D ‘scare card’.” Available at: http://www.tradewatch.org/documents/ACFDC.PDF
Quintiles Transnational (2001) “Promoting drugs through physician meetings and events: Pfizer leads the way; antidepressants are top category.” Available at: http://www.quintiles.com/products_and_services/informatics/scott_levin/press_releases/press_release/1,1254,209,00.html
Rang, H. P. (2006) “The receptor concept: Pharmacology’s big idea.” British Journal of Pharmacology, vol. 147, Suppl., pp. S9–S16.
Robinson, J. T. (November 2003). Changing the Face of Detailing by Motivating Physicians to See Pharmaceutical Sales Reps. Health Banks. Available at: http://www.healthbanks.com/PatientPortal/Public/support_documents/PMT_Robinson.pdf
Roche Pharmaceuticals (2008) “Innovative R&D.” Available at: http://www.rocheusa.com/r&d/overview.html
Schweitzer, S. O. (1997) Pharmaceutical Economics and Policy. Oxford: Oxford University Press.
Schweitzer, S. (2006) Pharmaceutical Economics and Policy. Oxford: Oxford University Press.
SciDeve (2008) “Universities urged: ‘Share benefits of health research’.” Available at: http://www.scidev.net/en/news/universities-urged-share-benefits-of-health-rese.html
Seppa, N. (18 and 25 December 1999) “With new vaccine, scientists prevent rabies in boys.” Science News, vol. 156, nos 25 and 26, p. iv.
Swann, J. (2007) “History of FDA.” US Department of Health and Human Services. Available at: http://www.fda.gov/oc/history/historyoffda/default.htm)
The American Heritage Science Dictionary (2007) Houghton Mifflin Company, dictionary.com.
The World Medical Association (2004) “Declaration of Helsinki.” Available at: be http://www.amsa.org/hp/reimportation.cfm
Trombetta, B. (1 September 2005) “2005 Industry Audit.” Pharmaceutical Executive. Available at: http://www.pharmexec.com/pharmexec/article/articleDetail.jsp?id=177964
US Department of Health and Human Services (August 1999) “FDA Guidance for Industry on Consumer-Directed Broadcast Advertisements.” Available at: http://www.fda.gov/cder/guidance/1804fnl.htm
US Department of Health and Human Services (29 September 2006) “News release: Medicare release data on 2007 drug plan options.” Available at: http://www.hhs.gov/news/press/2006pres/20060929.html
US Department of Health and Human Services (2007a) “Regulating Cosmetics, Devices, and Veterinary Medicine After 1938.” Available at: http://www.fda.gov/oc/history/historyoffda/section4.html
US Department of Health and Human Services (2007b) “The 1906 Food and Drugs Act and Its Enforcement”. Available at: http://www.fda.gov/oc/history/historyoffda/section1.html
US Government Technology Administration (9 May, 2002) “Testimonies on the virtue of the Bayh-Dole Act.” Available at: http://www.technology.gov/Speeches/BPM_020509_PCAST.htm
USA Today (2002) “How to buy prescription drugs at over 50 percent off US prices.” Available at: http://www.kirknews.com/newpage1.htm
Visongain (May 2006) “World generics market: 2006–2011.” Available at: http://www.piribo.com/publications/generic_drugs/world_generics_market_20062011.html
Watson, J. (2001) The Double Helix: A Personal Account of the Discovery of the Structure of DNA. New York: Touchstone.
Wikipedia (2007a) “History of medicine.” Available at: http://en.wikipedia.org/wiki/History_of_medicine#Modern_medicine
Wikipedia (2007b) “Pharmaceutical companies.” Available at: http://en.wikipedia.org/wiki/Pharmaceutical_companies
Wikipedia (2007c) “Pharmacology.” Available at: http://en.wikipedia.org/wiki/Pharmacology
Wood McKinzie Productview (March 2007) “Global company sales summary.” Available at: http://www.p-d-r.com/ranking/2006_Company_Sales.pdf
Author information
Authors and Affiliations
Copyright information
© 2009 Mei-Ling Wang
About this chapter
Cite this chapter
Wang, ML. (2009). The Modern Pharmaceutical Industry: History, Current Position and Challenges. In: Global Health Partnerships. Palgrave Macmillan, London. https://doi.org/10.1057/9780230582873_2
Download citation
DOI: https://doi.org/10.1057/9780230582873_2
Publisher Name: Palgrave Macmillan, London
Print ISBN: 978-1-349-35398-9
Online ISBN: 978-0-230-58287-3
eBook Packages: Palgrave Business & Management CollectionBusiness and Management (R0)